| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of thrombotic thrombocytopenic purpura associated with COVID-19
|
Nicolotti, Davide
|
|
|
52 |
2 |
p. 468-470
|
artikel
|
| 2 |
Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study
|
Lai, Nhu
|
|
|
52 |
2 |
p. 414-418
|
artikel
|
| 3 |
Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy
|
Livneh, Nir
|
|
|
52 |
2 |
p. 590-596
|
artikel
|
| 4 |
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
|
Pavoni, Vittorio
|
|
|
52 |
2 |
p. 542-552
|
artikel
|
| 5 |
Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease
|
Verdoia, Monica
|
|
|
52 |
2 |
p. 523-531
|
artikel
|
| 6 |
Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients
|
Ho, Gwendolyn
|
|
|
52 |
2 |
p. 476-481
|
artikel
|
| 7 |
Awareness of thrombotic disease during lockdown: an unusual consequence of the COVID-19 pandemic
|
Speletas, Matthaios
|
|
|
52 |
2 |
p. 466-467
|
artikel
|
| 8 |
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics
|
Camire, Rodney M.
|
|
|
52 |
2 |
p. 383-390
|
artikel
|
| 9 |
Characteristics of carotid atherosclerosis in patients with plaque erosion
|
Kato, Ayami
|
|
|
52 |
2 |
p. 620-627
|
artikel
|
| 10 |
Circle or semi‐circle hyper‐intensity on T1 high‐resolution isovolumetric examination (THRIVE) indicates the young age of experimentally induced caval thrombus
|
Shi, Wanyin
|
|
|
52 |
2 |
p. 628-634
|
artikel
|
| 11 |
Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia
|
Marashi-Sabouni, Zeina
|
|
|
52 |
2 |
p. 601-609
|
artikel
|
| 12 |
Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus
|
Bass, Megan E.
|
|
|
52 |
2 |
p. 517-522
|
artikel
|
| 13 |
Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients
|
Gibson, Caitlin M.
|
|
|
52 |
2 |
p. 577-583
|
artikel
|
| 14 |
Coronary artery aneurysm presenting as acute coronary syndrome: two case reports and a review of the literature
|
Taskesen, Tuncay
|
|
|
52 |
2 |
p. 683-688
|
artikel
|
| 15 |
COVID 19 infection associated with thrombotic thrombocytopenic purpura
|
Dhingra, Gaurav
|
|
|
52 |
2 |
p. 504-507
|
artikel
|
| 16 |
Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti-coagulants and beyond
|
Milstone, Leonard M.
|
|
|
52 |
2 |
p. 408-413
|
artikel
|
| 17 |
Downregulating LncRNA XIST attenuated contrast-induced nephropathy injury via regulating miR-133a-3p/NLRP3 axis
|
Liu, Xingli
|
|
|
52 |
2 |
p. 440-453
|
artikel
|
| 18 |
Ecchymosis in critical coronavirus disease 2019 (COVID-19) patient in Tangerang, Indonesia: a case report
|
Widysanto, Allen
|
|
|
52 |
2 |
p. 635-639
|
artikel
|
| 19 |
Evaluation of direct thrombin inhibitors during a critical heparin shortage
|
Ji, Christine S.
|
|
|
52 |
2 |
p. 662-673
|
artikel
|
| 20 |
Factor Xa inhibitors: critical considerations for clinical development and testing
|
Becker, Richard C.
|
|
|
52 |
2 |
p. 397-402
|
artikel
|
| 21 |
Factor Xa: Thrombokinase from Paul Morawitz to J Haskell Milstone
|
Milstone, Leonard M.
|
|
|
52 |
2 |
p. 364-370
|
artikel
|
| 22 |
From basic science to life-saving therapy: the rationale, and drug discovery efforts that led to the direct factor Xa inhibitor eliquis
|
Knabb, Robert M.
|
|
|
52 |
2 |
p. 403-407
|
artikel
|
| 23 |
Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?
|
Lim, Hui Yin
|
|
|
52 |
2 |
p. 610-619
|
artikel
|
| 24 |
Guest editors’ introduction
|
Milstone, Leonard M.
|
|
|
52 |
2 |
p. 363
|
artikel
|
| 25 |
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies
|
Kuno, Toshiki
|
|
|
52 |
2 |
p. 419-428
|
artikel
|
| 26 |
Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: a prospective cohort study
|
Pellegrini, José Augusto Santos
|
|
|
52 |
2 |
p. 482-492
|
artikel
|
| 27 |
Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis
|
Chen, Bo
|
|
|
52 |
2 |
p. 553-559
|
artikel
|
| 28 |
Management of isolated distal deep–vein thrombosis with direct oral anticoagulants in the RIETE registry
|
Galanaud, Jean-Philippe
|
|
|
52 |
2 |
p. 532-541
|
artikel
|
| 29 |
Massive pulmonary embolism in a patient with nephrotic syndrome and single lung
|
Shi, Hong Kai
|
|
|
52 |
2 |
p. 680-682
|
artikel
|
| 30 |
MicroRNA-520d-3p alleviates hypoxia/reoxygenation-induced damage in human cardiomyocytes by targeting ATG-12
|
Wu, Kunpeng
|
|
|
52 |
2 |
p. 429-439
|
artikel
|
| 31 |
Nonadministration of pharmacologic venous thromboembolism prophylaxis is less common in hospitalized patients with COVID-19
|
Varasteh Kia, Mujan
|
|
|
52 |
2 |
p. 471-475
|
artikel
|
| 32 |
Ovarian vein thrombosis after coronavirus disease (COVID-19) mimicking acute abdomen: two case reports
|
Fatimazahra, Merzouk
|
|
|
52 |
2 |
p. 493-496
|
artikel
|
| 33 |
Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus
|
Yeung, Wesley
|
|
|
52 |
2 |
p. 654-661
|
artikel
|
| 34 |
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting
|
Afzal, Saima
|
|
|
52 |
2 |
p. 646-653
|
artikel
|
| 35 |
Prothrombinase: the paradigm for membrane bound enzyme complexes; a memoir
|
Mann, Kenneth G.
|
|
|
52 |
2 |
p. 379-382
|
artikel
|
| 36 |
Pulmonary manifestations of antiphospholipid syndrome: a retrospective analysis of 67 patients
|
Sarinc Ulasli, Sevinc
|
|
|
52 |
2 |
p. 640-645
|
artikel
|
| 37 |
Roles of factor Xa beyond coagulation
|
Ruf, Wolfram
|
|
|
52 |
2 |
p. 391-396
|
artikel
|
| 38 |
Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design
|
Cardinal, Rachael M.
|
|
|
52 |
2 |
p. 567-576
|
artikel
|
| 39 |
Structure and function of factor X: properties, activation, and activity in prothrombinase. A retrospective in a historical context
|
Jackson, Craig M.
|
|
|
52 |
2 |
p. 371-378
|
artikel
|
| 40 |
Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm
|
Nauseef, Jones T.
|
|
|
52 |
2 |
p. 597-600
|
artikel
|
| 41 |
Switching between direct oral anticoagulants: a systematic review and meta-analysis
|
Romoli, Michele
|
|
|
52 |
2 |
p. 560-566
|
artikel
|
| 42 |
The effect of hydroxychloroquine on platelet activation in model experiments
|
Schreiber, Karen
|
|
|
52 |
2 |
p. 674-679
|
artikel
|
| 43 |
The risk of venous thromboembolism and physical activity level, especially high level: a systematic review
|
Danin-Mankowitz, H.
|
|
|
52 |
2 |
p. 508-516
|
artikel
|
| 44 |
The role of β-catenin in pulmonary artery endothelial-mesenchymal transformation in rats with chronic thromboembolic pulmonary hypertension
|
Zeng, Meie
|
|
|
52 |
2 |
p. 454-465
|
artikel
|
| 45 |
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?
|
Lapietra, Gianfranco
|
|
|
52 |
2 |
p. 584-589
|
artikel
|
| 46 |
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19
|
Marco, A
|
|
|
52 |
2 |
p. 497-503
|
artikel
|
Tijdschrift beschrijving